1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Akeso, Inc.
  6. Summary
    9926   KYG0146B1032

AKESO, INC.

(9926)
  Report
Delayed Hong Kong Stock Exchange  -  05/20 04:08:13 am EDT
13.98 HKD   +3.86%
04/14Akeso, Inc. Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at the American Association for Cancer Research 2022 Annual Meeting
CI
04/14Akeso, Inc. Announces Publication of Preclinical Results of Its Anti-TIGIT Monoclonal Antibody
CI
04/05UBS Adjusts Akeso's Price Target to HK$29.60 From HK$32.40, Keeps at Buy
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
05/16/2022 05/17/2022 05/18/2022 05/19/2022 05/20/2022 Date
12.56(c) 13.2(c) 13.5(c) 13.46(c) 13.98(c) Last
4 554 844 5 152 857 3 555 000 4 167 140 4 503 035 Volume
+1.78% +5.10% +2.27% -0.30% +3.86% Change
More quotes
Estimated financial data (e)
Sales 2022 1 051 M 157 M 157 M
Net income 2022 -940 M -140 M -140 M
Net cash position 2022 641 M 95,7 M 95,7 M
P/E ratio 2022 -10,3x
Yield 2022 -
Sales 2023 2 134 M 319 M 319 M
Net income 2023 -525 M -78,4 M -78,4 M
Net Debt 2023 124 M 18,5 M 18,5 M
P/E ratio 2023 -18,8x
Yield 2023 -
Capitalization 9 740 M 1 455 M 1 455 M
EV / Sales 2022 8,66x
EV / Sales 2023 4,62x
Nbr of Employees 1 865
Free-Float 64,9%
More Financials
Company
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets. 
More about the company
Ratings of Akeso, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about AKESO, INC.
04/14Akeso, Inc. Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at th..
CI
04/14Akeso, Inc. Announces Publication of Preclinical Results of Its Anti-TIGIT Monoclonal A..
CI
04/05UBS Adjusts Akeso's Price Target to HK$29.60 From HK$32.40, Keeps at Buy
MT
04/01Nomura Adjusts Akeso's Price Target to HK$35.81 From HK$53.66, Keeps at Buy
MT
03/30Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/07Akeso, Inc. Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadon..
CI
03/07Akeso Cleared to Start Phase II Study in China of Combination Therapy for Lung Cancer
MT
03/02Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Ca..
PR
03/02Akeso, Inc. Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evalu..
CI
03/02Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for L..
MT
03/02Akeso announced collaboration with chipscreen biosciences to initiated a clinical trial..
PR
02/10Akeso, Inc.'s NGF Monoclonal Antibody Approved to Initiate Clinical Trial in Pain (Incl..
CI
02/10Akeso Cleared to Start Clinical Trial in China of Analgesic for Cancer Pain; Shares Jum..
MT
01/30Akeso's Ligufalimab and Ivonescimab Obtained Approval to Initiate a Phase II Trial
CI
01/30Akeso, Inc. Announces First Patient in the Phase III Trial of Ivonescimab Combined with..
CI
More news
News in other languages on AKESO, INC.
04/14Akeso, Inc. publie les résultats précliniques de l'anticorps bi-spécifique PD-1/CD73(AK..
04/14Akeso, Inc. Annonce la publication des résultats précliniques de son anticorps monoclon..
03/30Akeso, Inc. annonce ses résultats pour l'année complète se terminant le 31 décembre 202..
03/07Akeso, Inc. annonce l'approbation par l'ANSM chinoise de l'essai clinique de phase II d..
03/07Akeso autorisé à lancer une étude de phase II en Chine sur la thérapie combinée pour le..
More news
Analyst Recommendations on AKESO, INC.
More recommendations
Chart AKESO, INC.
Duration : Period :
Akeso, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKESO, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 11,92 CNY
Average target price 31,40 CNY
Spread / Average Target 163%
EPS Revisions
Managers and Directors
Yu Xia Chairman, President & Chief Executive Officer
Xiao Jie Xi Chief Financial Officer
Baiyong Li Executive Director, Chief Scientific Officer & SVP
Jun Wen Zeng Independent Non-Executive Director
Yan Xu Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
AKESO, INC.-58.88%1 455
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612